Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of belzutifan monotherapy in advanced PPGL, pNET, VHL disease-associated tumors, wild-type GIST, or advanced solid tumors with HIF-2alpha-related genetic alterations
CTR20222468Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), islet cell tumor, von Hippel–Lindau disease (VHL), gastrointestinal stromal tumor (GIST), sponsored by Merck & Co.. Started Dec 2022; status: active.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)islet cell tumorvon Hippel–Lindau disease (VHL)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on CTR20222468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222468.